Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daprodustat versus darbepoetin alfa in non-dialysis chronic kidney disease anemia
2016-000542-65Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2016
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anemia of renal disease and chronic kidney disease (CKD) comparing Daprodustat with Darbepoetin alfa (2 arms). Primary endpoint: Time to first occurrence of adjudicated major adverse cardiovascular event. Started Oct 2016; status: completed.
02
Drugs
daprodustatdarbepoetin alfa
03
Conditions
anemia of renal diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2016-000542-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000542-65.